Robert Coffin
Executive Chairman

Robert Coffin, PhD, is a virologist and biotech entrepreneur with deep experience developing HSV-based therapeutics. He invented T-VEC and co-founded BioVex, leading the program through clinical development and the company’s ~$1B acquisition by Amgen, where T-VEC was commercialized as Imlygic®.

He subsequently co-founded and led Replimune as CEO through its Nasdaq IPO and advancement of multiple RPx HSV oncology programs into late-stage clinical trials. Robert has overseen research, clinical development, regulatory, and partnering activities across several viral medicine platforms.